Dupilumab, a fully human monoclonal antibody against IL‐4Rα, has been approved for treating moderate‐to‐severe AD8 and has also been proved effective in patients with prurigo nodularis, pruritic lichenified nodules, lichen planus, and other pruritic disorders such as chronic pruritus of unknown origin, uremic pruritus, and malignancy‐associated pruritus.7 Here, IL4R is linked to lichen planus.